Nuveen LLC Invests $486,000 in 4D Molecular Therapeutics, Inc. $FDMT

Nuveen LLC bought a new position in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund bought 150,314 shares of the company’s stock, valued at approximately $486,000. Nuveen LLC owned 0.32% of 4D Molecular Therapeutics as of its most recent filing with the SEC.

Other institutional investors have also added to or reduced their stakes in the company. Y Intercept Hong Kong Ltd bought a new stake in 4D Molecular Therapeutics in the 1st quarter valued at $41,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of 4D Molecular Therapeutics during the 4th quarter worth $50,000. Velan Capital Investment Management LP bought a new stake in shares of 4D Molecular Therapeutics during the 4th quarter worth $56,000. Proficio Capital Partners LLC increased its holdings in 4D Molecular Therapeutics by 26.0% in the 1st quarter. Proficio Capital Partners LLC now owns 25,195 shares of the company’s stock worth $75,000 after purchasing an additional 5,195 shares in the last quarter. Finally, ProShare Advisors LLC grew its holdings in 4D Molecular Therapeutics by 30.1% during the 4th quarter. ProShare Advisors LLC now owns 16,369 shares of the company’s stock worth $91,000 after acquiring an additional 3,783 shares during the last quarter. 99.27% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have recently weighed in on FDMT. Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Saturday, August 30th. Barclays reduced their price objective on 4D Molecular Therapeutics from $45.00 to $38.00 and set an “overweight” rating for the company in a research note on Friday, May 9th. The Goldman Sachs Group dropped their target price on 4D Molecular Therapeutics from $51.00 to $44.00 and set a “buy” rating on the stock in a report on Friday, May 9th. Chardan Capital reiterated a “buy” rating and issued a $25.00 target price on shares of 4D Molecular Therapeutics in a research note on Tuesday, August 12th. Finally, Roth Capital cut their price objective on 4D Molecular Therapeutics from $44.00 to $38.00 and set a “buy” rating on the stock in a research report on Tuesday, August 12th. Eight equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, 4D Molecular Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $30.40.

4D Molecular Therapeutics Trading Up 2.2%

Shares of 4D Molecular Therapeutics stock opened at $6.61 on Friday. The firm has a market capitalization of $308.69 million, a PE ratio of -1.87 and a beta of 2.86. 4D Molecular Therapeutics, Inc. has a 12 month low of $2.23 and a 12 month high of $17.41. The business’s 50-day moving average price is $5.34 and its 200-day moving average price is $4.26.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its earnings results on Monday, August 11th. The company reported ($0.98) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.10). 4D Molecular Therapeutics had a negative net margin of 594,375.81% and a negative return on equity of 40.15%. The company had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.52 million. As a group, analysts predict that 4D Molecular Therapeutics, Inc. will post -2.84 earnings per share for the current fiscal year.

4D Molecular Therapeutics Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.